Copyright
©2009 Baishideng.
World J Gastrointest Oncol. Oct 15, 2009; 1(1): 47-54
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.47
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.47
FAMTX | ECF | EOX | CF | DCF | S1 | CS | |
Anemia | 10 | 8.0-13.1 | 8.6 | 26 | 18 | 4.0-12.8 | 26 |
Thrombocytopenia | 8 | 4.0-4.7 | 5.2 | 13 | 8 | 0.0-1.3 | 5 |
Neutropenia | 58 | 36.0-41.7 | 27.6 | 57 | 82 | 5.6-11.0 | 40 |
Febrile neutropenia | 20 | 8.0-9.3 | 7.8 | 12 | 29 | 0.0-1.0 | 3 |
Diarrhea | 7 | 2.6-6.0 | 11.9 | 8 | 19 | 3.0-7.7 | 4 |
Stomatitis | 1.3 | 2.2 | 27 | 21 | 0.0 | 1 | |
Hand-foot syndrome | 1 | 3.0-4.3 | 3.1 | 0.0 | 0 | ||
Nausea and vomitting | 5 | 10.2-17.0 | 11.4 | 17 | 14 | 1.0-5.6 | 11 and 4 |
Peripheral neuropathy | 0.4 | 4.4 | 3 | 8 | 2.0 | 0 | |
Lethargy | 16.6 | 24.9 | 14 | 19 | 2.0-5.1 | 4 | |
Alopecia1 | 42 | 44.2-56.0 | 28.8 | ||||
Increased creatinine | 3 | 1.0 | 0.0 | 0 | |||
Ref. | [8] | [8,9] | [9] | [12] | [12] | [16,17] | [16] |
Publication | Trial | Regimens | OS (number) | Selected regimens | Median | Age range | Proportion of elderly patients (70 years old or over) | Ref. | Country |
1991 | EORTC | 5-FU/Adriamycin/MMC (FAM) | 4 (79) | FAMTX | 58 | 23-69 | No information | [7] | EORTC |
5-FU/Adriamycin/Methotrexate (FAMTX) | 6 (81) | 57 | 28-77 | ||||||
1993 | Murad et al | FAMTX | 9 (30) | FAMTX | 58 | 26-72 | No information | [3] | Brazil |
Best supportive care (BSC) | 3 (10) | 57 | 30-71 | ||||||
1995 | Pyrhönen et al | 5-FU/Epirubicin/Methotrexate (FEMTX) | 12.3 (21) | FEMTX | 58 | 42-75 | No information | [5] | Finland |
BSC | 3.1 (20) | 58 | 42-71 | ||||||
1997 | Glimelius et al | 5-FU/Leucovorin/Etoposide (FLE) | 8 (31) | ELF | 64 | 45-75 | No information | [4] | Sweden |
BSC | 5 (31) | 63 | 40-74 | ||||||
1997 | Webb et al | EPI/CDDP/5-FU (ECF) | 8.9 (111) | ECF | 59 | 35-79 | No information | [8] | UK |
FAMTX | 5.7 (108) | 60 | 29-78 | ||||||
2000 | Vanhoefer et al | FAMTX | 6.7 (133) | Similar efficacy | 58 | 30-74 | No information | [44] | EORTC |
ELF | 7.2 (132) | 59 | 25-74 | ||||||
5-FU/CDDP (FUP) | 7.2 (134) | 57 | 24-74 | ||||||
2003 | JCOG9205 | 5-FU | 7.1 (105) | 5-FU | 63 | 27-75 | No information | [14] | Japan |
5-FU/CDDP (CF) | 7.3 (105) | 63 | 19-75 | ||||||
UFT/MMC | 6 (70) | 60.5 | 30-75 | ||||||
2006 | V325 | Docetaxel/CDDP/5-FU (DCF) | 9.2 (227) | DCF | 55 | 26-79 | 24%-25%1 | [10] | USA |
CDDP/5-FU (CF) | 8.6 (230) | 55 | 25-76 | ||||||
2007 | JCOG9912 | S1 | 11.4 (234) | S1 | 64 | 39-75 | No information | [17] | Japan |
5-FU | 10.8 (234) | 63 | 24-75 | ||||||
CPT11/Docetaxel | 12.3 (236) | 63 | 32-75 | ||||||
2008 | SPIRITS | S1 | 11 (150) | S1/CDDP | 62 | 28-74 | 17% | [18] | Japan |
S1/CDDP (CS) | 13 (148) | 62 | 33-74 | ||||||
2008 | REAL-2 | EPI/CDDP/capecitabine (ECX) | 9.9 (241) | EOX | 64 | 25-82 | No information | [9] | UK |
ECF | 9.9 (249) | 65 | 22-83 | ||||||
EPI/oxaliplatin/capecitabine (EOX) | 11.2 (239) | 62 | 25-80 | ||||||
EPI/oxaliplatin/5-FU (EOF) | 9.3 (235) | 61 | 33-78 | ||||||
2008 | Al-Batran et al | 5-FU/LV/Oxaliplatin (FLO) | 10.7 (112) | FLO | 64 | 33-86 | 41%-45%2 | [23] | AIO |
5-FU/LV/CDDP (FLP) | 8.8 (108) | 64 | 27-85 |
Publication | Trials | Patient eligibility | Successful regimens as adjuvant therapy | Adjuvant effect | Median | Range | Proportion of elderly patients (70 years old or over) | Ref. | Country |
2001 | INT-116 | Pathological stage IB/II/III/IVM0 | Surgery + Chemo (5-FU/LV)-Radiation (45Gy) | 9% at 3 years | 60 | 25-87 | No information | [31] | USA |
Surgery alone | 59 | 23-80 | |||||||
2006 | MAGIC | Clinical stage II or more (M0) | Surgery + perioperative EPI/CDDP/5-FU (ECF) | 13.6% at 5 years | 62 | 29-85 | 20.4% | [32] | UK |
Surgery alone | 62 | 23-81 | 21.3% | ||||||
2007 | ACTS-GC | Pathological stage II/IIIA/IIIB | Surgery + S1 | 10% at 3 years | 63 | 27-80 | 25.9% | [34] | Japan |
Surgery alone | 63 | 33-80 | 22.6% |
- Citation: Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009; 1(1): 47-54
- URL: https://www.wjgnet.com/1948-5204/full/v1/i1/47.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v1.i1.47